EUVIMEDEUVIMED entdecken
Crossref

Clinical and prognostic profiles in immune-mediated hypertrophic meningitis: a retrospective analysis of 92 cases

Yifei Wang, Yuyan Yang, Xuemei Guo, Hui You, Manqing Xie, Shangzhu Zhang, Yunjiao Yang, Di Wu, Linyi Peng, Yunyun Fei, Xinping Tian, Mengtao Li und 4 weitere

Clinical Rheumatology · 2025

DOI: 10.1007/s10067-025-07531-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Rheumatology, 2025. Verfasst von Yifei Wang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Peking Un…. Hauptthemen laut MEDLINE: Meningitis, Immunoglobulin G4-Related Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Immune-mediated hypertrophic pachymeningitis (HP) is an inflammatory disorder with diverse neurological manifestations. Considering its various etiology and rarity, HP remains a diagnostic challenge. Comparisons of clinical and prognostic profiles across different etiologies remain insufficiently explored. We analyzed the clinical characteristics, treatment approaches, and outcomes of immune-mediated HP patients from a single center in China. METHOD: A retrospective study was conducted at Peking Union Medical College Hospital, analyzing immune-mediated HP cases from December 2003 to September 2021. We evaluated patients' neurological symptoms, systemic involvement, image findings, and baseline laboratory results, and compared these features among three predominant etiologies: antineutrophil cytoplasmic antibody (ANCA)-related HP, idiopathic HP, and IgG4-related disease (IgG4-RD). The treatment approaches and outcomes were also reviewed. RESULTS: The study included 92 patients, 49 (53.3%) male and 43 (46.7%) female. ANCA-related HP was the leading cause of immune-mediated HP (n = 42, 45.6%), followed by idiopathic HP (n = 28, 30.4%), IgG4-RD (n = 12, 13.0%), and other underlying causes (n = 10, 10.9%). Despite different etiologies, similar patterns of cranial nerve and brain region involvement were observed. Large doses of glucocorticoids combined with immunosuppressants were the most common treatment across all etiologies. Kaplan-Meier analysis (mean follow-up time: 4.1 years) showed no significant differences in relapse-free survival rates among the three subgroups. CONCLUSIONS: ANCA-related HP, idiopathic HP, and IgG4-RD HP were the three predominant causes of immune-mediated HP in this Chinese cohort. The three etiologies exhibited similar clinical manifestations, imaging findings, and long-term prognoses, indicating that a standardized management strategy may benefit HP patients regardless of etiology. Key Points • Immune-mediated hypertrophic pachymeningitis (HP) is a rare disorder with diverse etiologies, and research comparing clinical and prognostic profiles across different causes remains limited. • This study involved 92 immune-mediated HP patients, comparing clinical characteristics, imaging findings, treatment approaches, and outcomes among ANCA-related, idiopathic, and IgG4-related HP. • The three predominant etiologies of HP showed similar clinical features and similar relapse-free survival rates. • Regardless of the underlying etiology, HP patients may benefit from a uniform management approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningitisImmunoglobulin G4-Related DiseaseHumansFemaleMaleRetrospective StudiesMiddle AgedAdultPrognosisAgedChinaAntibodies, Antineutrophil CytoplasmicYoung AdultHypertrophyAdolescentImmunosuppressive Agents

Stichwörter der Autor:innen

Immunoglobulin G4-related diseaseMeningitisPrognosisVasculitis

Substanzen

Antibodies, Antineutrophil CytoplasmicImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Pe…
  • Department of Plastic and Reconstructive Surgery, Peking Union Medical College Hospital, Beijing, China.
  • Department of Rheumatology, General Hospital of Northern Theater Command, Shenyang, China.
  • Department of Radiology, Peking Union Medical College Hospital, Beijing, China.
  • Department of Neurology, Peking Union Medical College Hospital, Beijing, China.

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Natural Science Foundation of Beijing Municipality
  • Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park
  • PUMCH Science Fund for Young Scholars

Zitieren

APA

Wang, Y., Yang, Y., Guo, X., You, H., Xie, M., Zhang, S., Yang, Y., Wu, D., Peng, L., Fei, Y., Tian, X., Li, M., Zhao, Y., Zeng, X., Zhang, W., & Zhou, J. (2025). Clinical and prognostic profiles in immune-mediated hypertrophic meningitis: a retrospective analysis of 92 cases. Clinical Rheumatology. https://doi.org/10.1007/s10067-025-07531-8

Vancouver

Wang Y, Yang Y, Guo X, You H, Xie M, Zhang S, et al. Clinical and prognostic profiles in immune-mediated hypertrophic meningitis: a retrospective analysis of 92 cases. Clinical Rheumatology. 2025. doi:10.1007/s10067-025-07531-8

BibTeX
@article{Wang2025,
  author = {Wang, Yifei and Yang, Yuyan and Guo, Xuemei and You, Hui and Xie, Manqing and Zhang, Shangzhu and Yang, Yunjiao and Wu, Di and Peng, Linyi and Fei, Yunyun and Tian, Xinping and Li, Mengtao and Zhao, Yan and Zeng, Xiaofeng and Zhang, Wen and Zhou, Jiaxin},
  title = {Clinical and prognostic profiles in immune-mediated hypertrophic meningitis: a retrospective analysis of 92 cases},
  journal = {Clinical Rheumatology},
  year = {2025},
  doi = {10.1007/s10067-025-07531-8}
}
Kostenlos starten →